echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The highest collective volume of negotiation varieties of anticancer drugs increased by 85800%

    The highest collective volume of negotiation varieties of anticancer drugs increased by 85800%

    • Last Update: 2019-04-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In 2017, the former Ministry of human resources and social security led the first batch of medical insurance negotiations, and in 2018, the newly established National Medical Insurance Bureau launched special negotiations on anticancer drugs In the future, the negotiation of innovative medicine medical insurance will become one of the routine work of the State Medical Insurance Bureau According to the data of PDB sample hospitals, in 2018, the quantity of special negotiation varieties of anticancer drugs was significant, and the sales volume of Q4 increased by 85800% at most, with an average increase of 6718% In 2017, 36 negotiation varieties continued to be large-scale, with both sales volume and sales volume surging collectively Price negotiation will be one of the important ways to adjust the national health insurance catalogue in 2019 With the more and more successful access to medical insurance, multinational pharmaceutical companies have regarded the introduction of innovative drugs into medical insurance as one of the key tasks A number of multinational pharmaceutical companies have publicly expressed their hope to include innovative drugs in medical insurance The highest growth rate of special negotiation varieties of anticancer drugs is 30420% In 2018, the National Health Insurance Bureau launched special negotiation on anticancer drugs In October 2018, the Medical Insurance Bureau officially included 17 kinds of anticancer drugs such as enrotinib in the medical insurance catalogue Through PDB data calculation, 2018q4 terminal price has basically executed the negotiation price Since the special negotiation varieties of anticancer drugs were only released in October 2018, the increasing effect of the sales volume of collected varieties in Q4 2018 has not been obvious, and the sales volume of some varieties decreased compared with the first three quarters of 2018 But the sales volume of all varieties has been greatly improved For example, Merck cetuximab, which failed in the medical insurance negotiation in 2017, saw a year-on-year growth of - 8%, 17% and - 4% in the first three quarters of 2018 After Q4 entered the medical insurance catalogue in 2018, the sales increased by 146% Pfizer's three anticancer drugs, acitinib, clozatinib and sunitinib, entered the medical insurance catalog through special negotiations From the sales data, in the first three quarters of 2018, the sales volume and sales growth of the three products were negative Driven by medical insurance, sales increased by 610%, 258% and 47% respectively, and sales increased by 109%, 10% and - 36% respectively There are also several new drugs that have just come into the market, and they will enter the medical insurance catalogue soon after they come into the market in China The pull effect of medical insurance is very obvious For example, in 2018, the sales growth of alfatini of bringer Ingelheim was only 50%, after entering the medical insurance catalog, the sales growth of Q4 was 7689%, and the sales growth was 4289% Novaprazole was launched in China in March 2017 Pezopanil was listed in the United States in 2009, and its volume is not significant after that In 2016, global sales increased to $729 million After China's inclusion in the medical insurance catalogue, sales in 2018q4 increased by 17060% and sales by 6064% Ibutini of Johnson & Johnson went public in China in August 2017 After the launch of the product, the global growth is rapid, and the global sales in 2017 exceeded 4.5 billion US dollars After being included in the medical insurance catalogue, its sales volume soared by 85800% and 30420% in 2018q4 The highest growth rate of 36 negotiation varieties was 1139% On July 19, 2017, the original Ministry of human resources and social security released a catalogue of 36 negotiation varieties, including 31 Western medicines and 5 Chinese patent medicines PDB data shows that in 2017, Q4 terminal price has basically implemented the negotiation price, and the volume effect brought by price reduction is very obvious Most varieties achieved a significant increase in sales volume and sales growth In 2018, the pulling effect of medical insurance catalogue on negotiation varieties continued to show, with 36 negotiation varieties realizing "price for quantity" The highest growth rate of sales of 36 products reached 1139%, and the highest growth rate of sales reached 1222% From the perspective of imported varieties, Roche's trastuzumab decreased by 65%, sales increased by 259% and 47.76% in 2018; bevacizumab decreased by 62%, sales increased by 205% and sales increased by 74% in 2018 Lenalidomine of new base biology decreased by 60%, sales increased by 904% and 523% in 2018 From the perspective of domestic varieties, Hengrui apatini reduced its price by 37%, with a year-on-year growth of 125% and a year-on-year growth of 67% in sales in 2018 Conbercept reduced its price by 17%, and its sales volume increased by 63% and 49% year on year in 2018 In 2018, the products with sales growth of more than 500% year-on-year include: new base lenalidomide (52.3%), abitrone of Janssen (59.4%), alisartan ester of xinlitai (89.2%), midabendamine of microchip (59.5%), moroxynidazole sodium chloride injection of Haosen Pharmaceutical (113.9%) From the data point of view, the combination of price reduction and medical insurance reimbursement has a very strong pulling effect on the volume of innovative drugs Multinational pharmaceutical companies: it is hoped that innovative drugs will be introduced into the medical insurance catalogue in 2019 and the adjustment work is already in hot progress According to Shenwan Hongyuan research, the working procedure of the 2019 version of the draft is extremely compact, and it takes less than six months from the publication of the draft to the completion of the catalog adjustment This stylized and efficient adjustment scheme will speed up the implementation of the catalog adjustment from the publication of the catalog to the landing The varieties that enter the national medical insurance catalogue have great advantages in bidding, hospital access and market promotion, and have always been the best way for large quantity of drugs in China's pharmaceutical market After the previous rounds of drug price negotiations and anti-cancer drug collection, the national level has a relative grasp of the product price In addition, after the reform of most systems, the state health insurance bureau has integrated the right to bid and purchase, so that there are no more constraints in the exchange of price for quantity It is also the policy guidance of the state to enter into the medical insurance catalogue through drug price negotiation, supported by various policies At the end of 2018, the health administration of the national health and Health Commission issued the notice on the allocation and use of anticancer drugs in 17 national health insurance negotiations, which mentioned that hospitals should not influence the supply guarantee and rational drug demand of negotiated drugs on the grounds of total control of medical expenses, total control of medical insurance expenses, "drug proportion" and quantity limit of drug varieties This is the first time that the national level has released the signal of "the proportion of negotiated varieties not accepted as drugs" Before that, in fact, many provinces in the country have issued policies, saying that the drugs negotiated by the state are not included in the drug proportion assessment In the long run, with the implementation of centralized procurement and the reform of medical insurance payment mode, medical insurance management is becoming more and more refined It is also the general trend to cancel the simple and crude management mode of "drug proportion" Without the shackles of drug proportion, it will be more conducive to the volume of medical insurance drugs A number of multinational pharmaceutical companies have clearly released the signal that they want to include innovative drugs in the medical insurance catalog On March 30, 2019, rituximab, a blockbuster target drug of Roche, was officially launched in China, opening the era of dual target therapy for breast cancer with Herceptin For the new drug, Zhou Hong, President of Roche China, said in an interview with the media: "our biggest hope is to bring pajite into the national health insurance through the update of the health insurance catalog in 2019, so as to really improve the accessibility of patients." Roche had four anti-cancer targeted drugs entered the national health insurance catalog through negotiation According to e-drug managers, Roche's sales in China surged by 75% in 2018, with sales growth of 28% Roche said that in 2019, it hopes to include four other biological drugs in the new medical insurance catalog, namely, pajit, ansanza, shuyoulile and yamelo, the rheumatic immune drug approved in 2018 Paul Han, Global CEO of Novartis, recently told e-drug managers that he hoped to include novinol, an innovative drug for the treatment of heart failure, in the national health insurance catalog adjustment in 2019 Novotel was listed in China in July 2017, only two years after FDA approval Currently, the world is in a period of rapid growth, with global sales reaching US $1 billion in 2018 It is also worth noting that Xi'an Janssen and Shanghai bolingyingehan Recently, Xi'an Janssen's cagreen and Bi's engereen have applied for price reduction in Liaoning and Chongqing These two antidiabetic drugs are new faces within two years of being listed in China, which should have been in a rapid release period However, dagglijing, a similar product of AstraZeneca, was previously included in the basic drug list, and will probably be included in the medical insurance list Xi'an Janssen and Bi's move is undoubtedly a step ahead of entering the medical insurance market These products are expected to enter the 2019 medical insurance catalog Shen wanhongyuan thinks that according to the 2019 version of the draft for comments, basic drugs, cancer, rare diseases and chronic diseases will be focused on in this round of medical insurance catalog adjustment Therefore, the non-medical insurance varieties in the 2018 version of the basic drug catalog are expected to be included in the medical insurance catalog through this adjustment In addition, the class B medical insurance varieties in the basic drug catalog are also given priority in the process of class a adjustment In addition, the clinical just needed varieties, such as pyrrolidine and furaquinidine, which were launched after the negotiation in 2017, are also expected to be included in the adjustment.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.